[Acceptability and short-term tolerance to an orally administered new formulation of magnesium (TX 1341) compared to that of a reference magnesium].
Paccalin
J
J
Gelas
B
B
Herbrecht
F
F
Torres
C
C
Chevallier
T
T
Micheletti
M C
MC
D000284:Administration, Oral; D002626:Chemistry, Pharmaceutical; D019343:Citric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007773:Lactates / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D008274:Magnesium / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D008275:Magnesium Deficiency / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D017060:Patient Satisfaction; D011736:Pyridoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use
D007773:Lactates; D009942:Organometallic Compounds; D019343:Citric Acid; D008274:Magnesium; D011736:Pyridoxine; C110422:magnesium citrate
Acceptabilité et tolérance à court terme par voie orale d'une nouvelle formulation de magnésium (TX 1341) comparée à celle d'un magnésium de référence.